Eylea (aflibercept intravitreal) / Bayer, Regeneron  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

110 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Eylea (aflibercept intravitreal) / Regeneron
NCT01640171: Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

Completed
N/A
57
US
Xylocaine 2% Injectable Anesthetic, Lidocaine, Subconjunctival, Anesthesia, Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Topical, Tetravisc 0.5% Gel, topical, Acuvail, anti-inflammatory, ketorolac, Intra-vitreal Anti-VEGF Drug, Lucentis, Avastin, Eylea
Retina Vitreous Associates of Florida
Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
09/13
10/13
NCT02126904: Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept

Unknown status
N/A
200
Japan
IVA group
Yokohama City University Medical Center, Novartis Pharmaceuticals
The Injection Burden
10/13
 
NCT01526070: Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration

Completed
N/A
142
US
Intravitreal injection of Aflibercept
Stanford University
Exudative Age-related Macular Degeneration
07/14
07/14
NCT02000102: Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

Completed
N/A
14
US
Intravitreal Injection of Aflibercept
Stanford University
Diabetic Macular Edema
09/14
09/14
NCT01918371: A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

Completed
N/A
323
US
Anti-VEGF, Avastin®, Lucentis®, Eylea®
Allergan
Retinal Vein Occlusion, Macular Edema
09/14
09/14
AVA, NCT01965041: Intravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy

Withdrawn
N/A
0
US
aflibercept, eylea
Manhattan Eye, Ear & Throat Hospital, Northwell Health
Pattern Dystrophy of Macula
11/14
11/14
NCT02291887: Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept

Completed
N/A
13
US
Ranibizumab, Lucentis, Aflibercept, Eylea
Associated Retinal Consultants, Michigan, Genentech, Inc.
Age-Related Macular Degeneration
07/15
07/15
NCT01746875: A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes

Terminated
N/A
9
Europe
Aflibercept, Verteporfin
Norwegian University of Science and Technology
Macular Degeneration, Retinal Detachment
09/15
09/15
NCT01711879: Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma

Completed
N/A
7
US
Aflibercept, Eylea
University of Colorado, Denver
Neovascular Glaucoma
10/15
10/15
NCT02005133: A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics

Terminated
N/A
188
Europe
Novartis Pharmaceuticals
Wet Age-related Macular Degeneration
10/15
10/15
NCT02597855: Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy

Unknown status
N/A
29
RoW
Aflibercept, Eylea, Indocyanine green angiography (intraveonus indocyanine green dye)
Yeungnam University College of Medicine
Polypoidal Choroidal Vasculopathy
12/15
08/16
ATLAS, NCT01773954 / 2010-022184-35: Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

Checkmark ATLAS
May 2016 - May 2016: ATLAS
Completed
N/A
40
US
Intravitreal Aflibercept Injection
MidAtlantic Retina, Regeneron Pharmaceuticals
Age-Related Macular Degeneration, Macular Degeneration
03/16
03/16
NCT02541084: Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

Completed
N/A
72
Japan
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Wet Macular Degeneration
03/16
07/16
NCT02585401: Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

Completed
N/A
99
Canada
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), Diabetic Macular Edema (DME)
03/16
05/16
NCT01942213: Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.

Completed
N/A
136
US
Prism Vision Group
Neovascular Age Related Macular Degeneration
04/16
04/16
SWITCH, NCT04018833: Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema

Completed
N/A
40
NA
Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS], Aflibercept 40 MG/ML Intraocular Solution [EYLEA]
Bernardete Pessoa MD
Diabetic Macular Edema, Diabetic Retinopathy
06/16
06/16
NCT01991730: Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients

Recruiting
N/A
300
US
NJ Retina
Age Related Macular Degeneration
06/16
 
NCT01756261: EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan

Completed
N/A
757
Japan
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Macular Degeneration
07/16
02/17
NCT02218177: Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD

Completed
N/A
30
Canada
Aflibercept, Eylea (R), Ranibizumab, Lucentis, Combination Photodynamic Therapy
University Health Network, Toronto
Age Related Macular Degeneration
08/16
12/16
NCT02615496: Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept

Completed
N/A
716
Europe
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, RTI Health Solutions
Macular Degeneration
09/16
01/17
NCT03712670: Nutraceutical Support With Omega-3

Completed
N/A
60
NA
Aflibercept, Pranoprofen, Carotenoids
Università degli Studi di Brescia
Retinal Disease
12/16
03/17
TITAN, NCT02321241: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD

Completed
N/A
236
Europe
Aflibercept (EYLEA, BAY-86-5321)
Bayer, Regeneron Pharmaceuticals
Wet Macular Degeneration
01/17
08/17
PERSEUS, NCT01914380: Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration

Completed
N/A
988
Europe
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Wet Age-related Macular Degeneration
03/17
03/17
NCT03974425: One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab

Completed
N/A
37
NA
Aflibercept Injection [Eylea]
University of Alexandria
Diabetic Macular Edema
04/17
04/18
NCT02956330: Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201

Completed
N/A
20
US
Clearside Biomedical, Inc.
Macular Edema, Retinal Vein Occlusion
04/17
04/17
NCT03038048: 30g vs 33g Needle for Intravitreal Injections

Completed
N/A
50
US
Varying needle size with intravitreal ranibizumab or aflibercept, Lucentis, Eylea
Wills Eye, Mid Atlantic Retina
Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
04/17
04/17
NCT03313401: Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration

Completed
N/A
34
NA
Aflibercept, eylae, Specular microscopy, Tomey-EM-3000
Ulucanlar Eye Training and Research Hospital
Age Related Macular Degeneration
05/17
06/17
NCT01714115: Use of Eylea for the Treatment of an Optic Nerve Hemangioma

No Longer Available
N/A
US
Aflibercept, Eylea, VEGF Trap-Eye
Vitreous -Retina- Macula Consultants of New York, Regeneron Pharmaceuticals
Retinal Hemangioma
 
 
NCT02381730: Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment

Completed
N/A
37
Europe
Intravitreal aflibercept
Fondation Ophtalmologique Adolphe de Rothschild
Polypoidal Choroidal Vasculopathy
08/17
08/17
PEGASUS, NCT02540369: To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.

Completed
N/A
2150
Canada
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Wet Macular Degeneration
09/17
01/18
OIVAEGFFAMDIT, NCT03324542: Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan

Completed
N/A
63
RoW
Aflibercept [Eylea], Ranibizumab [Lucentis], Bevacizumab [Avastin]
Changhua Christian Hospital
AMD
10/17
10/17
CODEX, NCT02811692: Study for Collection of Aflibercept Data in Routine Practice

Completed
N/A
425
Europe
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Eye Diseases
11/17
11/17
ADDENDUM, NCT02554747: Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa

Completed
N/A
48
Europe
Navigated laser, Conventional laser
Odense University Hospital, Moorfields Eye Hospital NHS Foundation Trust
Diabetic Macular Oedema
12/17
11/18
RETRO CRVO, NCT02645747: Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion

Completed
N/A
126
Europe
Aflibercept (Eylea, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Retinal Vein Occlusion
12/17
12/17
INSIGHT, NCT03278262: The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting

Completed
N/A
2312
Europe
Aflibercept (Eylea, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Wet Macular Degeneration
12/17
12/17
NCT02457026: Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

Withdrawn
N/A
0
US
Aflibercept, Eylea, Triamcinolone Acetonide, Triesence, Verteporfin, Visudyne
Duke University, Bausch & Lomb Incorporated
Neovascular Age-related Macular Degeneration
01/18
01/18
NCT03509623: Blood Coagulation Parameters in Patients Receiving Intravitreal Aflibercept for Age-related Macular Degeneration

Completed
N/A
47
Europe
Blood sampling through direct peripheral venous puncture
University Hospital of Patras
Neovascular Age-related Macular Degeneration
03/18
04/18
NCT02260687: Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

Completed
N/A
353
Japan
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Choroidal Neovascularization
04/18
08/18
NCT03370380: Aflibercept in Patients With Pigment Epithelial Detachments (PED)

Completed
N/A
18
Europe
Aflibercept
University Hospital Muenster
Pigment Epithelial Detachment
04/18
04/18
JPMS-CRVO, NCT02040220: Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)

Completed
N/A
385
Japan
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Retinal Vein Occlusion
06/18
11/18
NCT04075188: Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid

Completed
N/A
17
Europe
Aflibercept Injection, verteporfin for injection
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Choroidal Neovascularization, Choroid Disease
06/18
07/19
NCT02812030: Aflibercept for Retinopathy in the Real World

Withdrawn
N/A
0
NA
National Eye Institute Visual Functioning Questionnaire, NEIVFQ-25
Timothy Jones, University Hospitals Bristol and Weston NHS Foundation Trust, Gloucestershire Hospitals NHS Foundation Trust
Diabetic Retinopathy
08/18
08/18
NCT04014556: Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema

Completed
N/A
40
NA
micropulse laser, Aflibercept
University of Alexandria
Diabetic Macular Edema
10/18
12/18
ASTERIA, NCT03382587: Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients

Completed
N/A
163
Europe
Aflibercept (Eylea, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Wet Age-related Macular Degeneration
11/18
11/18
GALAXY, NCT03521895: An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies

Completed
N/A
1000
Europe
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Bayer
Macular Degeneration
11/18
11/18
NCT01756248: EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan

Completed
N/A
3872
Japan
Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Macular Degeneration
12/18
05/19
NCT01783925: Eylea Post Marketing Surveillance(PMS)

Completed
N/A
3206
RoW
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Macular Degeneration
12/18
12/18
REALE, NCT03411941: Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)

Completed
N/A
116
Europe
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Macular Degeneration
03/19
03/19
PERSEUS-IT, NCT02289924: Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy

Completed
N/A
912
Europe
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Wet Macular Degeneration
03/19
07/19
RAINBOW, NCT02279537: Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

Completed
N/A
593
Europe
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Wet Macular Degeneration
04/19
04/19
NCT02425501: Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

Completed
N/A
646
Japan
Aflibercept (Eylea, BAY86-5321)
Bayer
Macular Edema
04/19
08/19
DRAKO, NCT02850263: A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema

Completed
N/A
750
Europe
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321), Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)
Bayer
Macular Edema
05/19
11/20
PERSEUS-GR, NCT02821247: Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece

Completed
N/A
119
Europe
Aflibercept (Eylea, BAY86-5321), VEGF Trap-Eye
Bayer
Choroidal Neovascularization, Macular Degeneration
07/19
12/19
APOLLON, NCT02924311: Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema

Completed
N/A
402
Europe
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Diabetic Retinopathy
08/19
12/19
DOCTA, NCT03783832: Follow up of Diabetic Macular Edema Treated by Aflibercept (Eylea®) With OCT-Angiography

Unknown status
N/A
48
Europe
OCT ANGIOGRAPHY DATA
Aquitania Opthalmologica
Diabetic Macular Edema
12/19
12/19
DME-OSA, NCT03597815: Diabetic Macular Edema - Obstructive Sleep Apnea Relationship Study

Active, not recruiting
N/A
150
Canada
Aflibercept 40 MG/ML [Eylea], OSA diagnostic test - overnight sleep study, CPAP therapy for OSA positive patients
Uptown Eye Specialists
Diabetic Macular Edema, Sleep Apnea, Non Proliferative Diabetic Retinopathy
03/20
12/20
NCT04067583: A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe

Completed
N/A
454
Europe
Physician questionnaire
Bayer
Ophthalmology, Macular Degeneration
04/20
04/20
MODEVA, NCT02874859: Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema

Completed
N/A
49
Europe
Lille Catholic University, Bayer
Diabetic Macular Edema
08/20
08/20
AQUILA, NCT03470103: A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America

Completed
N/A
643
RoW
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Bayer
Macular Degeneration
09/20
01/21
VITCLEAR, NCT02174211 / 2012-005500-18: A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.

Completed
N/A
59
Europe
Ranibizumab, Lucentis, Aflibercept, Eylea
King's College Hospital NHS Trust, King's College London
Age Related Macular Degeneration
11/20
12/20
NCT05110209: Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Completed
N/A
331541
US
Aflibercept, EYLEA®, Ranibizumab, LUCENTIS®, Bevacizumab, AVASTIN®; off-label use
Novartis Pharmaceuticals
Age-related Macular Degeneration (AMD)
11/20
11/20
NCT06146309: Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion

Completed
N/A
60
RoW
aflibercept (2mg/0.05ml)
Al-Azhar University
Branch Retinal Vein Occlusion
07/22
08/22
NCT05146687: Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Completed
N/A
369600
US
Aflibercept, EYLEA®, Ranibizumab, LUCENTIS®, Bevacizumab, AVASTIN®; off-label use
Novartis Pharmaceuticals
Age-related Macular Degeneration (AMD)
12/20
12/20
NCT05478967: The Effect of IVA for Preventing Postvitrectomy Hemorrhage in PDR

Completed
N/A
154
RoW
IVA injection before vitrectomy
Peking University People's Hospital, The First Affiliated Hospital with Nanjing Medical University, Shanghai 10th People's Hospital, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital of Nanchang University, Nanjing Medical University, Xiamen University
Proliferative Diabetic Retinopathy
01/21
02/21
AVOCT, NCT03394573: Comparison of VA Guided Versus OCT Guided TER Using Aflibercept for Diabetic Macular Edema ( Study)

Terminated
N/A
110
Europe
OCT guided treatment arm, aflibercept, VA guided treatment arm
University Hospital Inselspital, Berne
Diabetic Macular Edema
02/21
02/21
ChiCTR2100048700: Efficacy in pachychoroid spectrum disorders patients treated with intravitreal aflibercept

Completed
N/A
60
 
Intravitreal Aflibercept ;Intravitreal Conbercept
The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, Su Zhou science and technology programs
pachychoroid spectrum disorders
 
 
NCT03908723: Treatment of Macular Edema Caused by Leber's Miliary Aneurysms Using Intravitreal Aflibercept and Peripheral Laser Photocoagulation

Unknown status
N/A
6
RoW
Panretinal photocoagulation
Alexandria University
Macular Edema Caused by Leber's Miliary Aneurysms
03/21
05/21
NCT04970251: Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma

Completed
N/A
5
RoW
Aflibercept Ophthalmic, trabeculectomy, Panretinal photocoagulation
Siriraj Hospital
Intraocular Pressure, Neovascular Glaucoma, Vascular Endothelial Growth Factor Overexpression, Glaucoma Secondary to Eye Inflammation
03/21
03/21
BELUGA, NCT04641234: A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).

Completed
N/A
330
Europe
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer
Neovascular Age-related Macular Degeneration
06/21
06/21
NCT04856397: Ozurdex in Suboptimal Diabetic Macular Edema Patients

Not yet recruiting
N/A
200
NA
Intravitreal Implant in Applicator, Ozurdex, Eylea
Uptown Eye Specialists
Diabetic Macular Edema
08/21
12/21
AURIGA, NCT03161912: A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease

Completed
N/A
2481
Europe, RoW
Aflibercept (Eylea, BAY86-5321)
Bayer, Regeneron Pharmaceuticals
Macular Edema
09/21
12/21
NCT04891835: Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU Brugmann

Completed
N/A
36
Europe
Data extraction from medical files
Laurence Postelmans
Age-related Macular Degeneration
09/21
09/21
NIRVANA, NCT03651011: Navigated Laser In Branch Retinal Vein Occlusion Study

Completed
N/A
47
Europe
Aflibercept Injection [Eylea], Navigated laser photocoagulation, Navilas
Odense University Hospital, Danske Regioner, Synoptik-Fonden, Toyota-Fonden, AP Moeller Foundation, Yamagata University, Queen's University, Belfast, Zealand University Hospital, Region Sjællands og Region Syddanmarks forskningspulje
Branch Retinal Vein Occlusion, Macular Edema
10/21
10/21
ChiCTR2100049055: A multicenter, randomized controlled trial of advanced age-related macular degeneration

Not yet recruiting
N/A
40
 
IBI302 treatment ;Treatment of EYLEA
Shanghai General Hospital; Shanghai General Hospital, project funding
age-related macular degeneration
 
 
NCT04882956: BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

Recruiting
N/A
40
RoW
intravitreal injection, BEOVU, Eylea
Benha University
Macula Lutea Degeneration
12/21
03/22
NCT05080803: Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome

Completed
N/A
608
Europe
intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone
European School of Advanced Studies in Ophthalmology
Diabetic Macular Edema
12/21
07/22
NCT02081339: Cohort Study of the Clinical Course of Macular Diseases in Japanese

Recruiting
N/A
1000
Japan
ranibizumab, aflibercept, pegaptanib, verteporphin
Kyoto University, Graduate School of Medicine
Macular Disease
03/22
03/24
NCT02550002: Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen

Completed
N/A
150
Europe
Aflibercept, Eylea
University Hospital Inselspital, Berne
Age Related Macular Degeneration
03/22
08/22
NCT05731089: IVI Aflibercept Before and After Phaco in DME.

Completed
N/A
40
RoW
Phacoemulsification with IVI of aflibercept
Al Hadi Hospital
Diabetic Macular Edema
08/22
12/22
NAAVA, NCT04137120: Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice

Completed
N/A
73
RoW
Aflibercept (BAY86-5321, Eylea), Eylea®; Eylia®; Wetlia®; VEGF Trap-Eye
Bayer
Retinal Disease
08/22
02/23
REALM, NCT04524910: A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)

Completed
N/A
28
Canada
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Bayer
Myopic Choroidal Neovascularization
10/22
11/22
NCT04707027: Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept

Recruiting
N/A
80
RoW
Aflibercept Injection (2 mg/0.05 ml), Eylea, Defer treatment
Chiang Mai University
Polypoidal Choroidal Vasculopathy
11/22
11/23
NCT03290794: Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

Completed
N/A
100
RoW
Aflibercept (Eylea, BAY86-5321)
Bayer
Wet Age-related Macular Degeneration
11/22
05/23
HERMES Study, NCT02880644: Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept

Completed
N/A
65
Europe
Centre Hospitalier Intercommunal Creteil, Bayer, Association Clinique Thérapeutique Infantile du val de Marne
Retinal Vein Occlusion
11/22
11/22
NCT05791695: A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022

Completed
N/A
155413
US
Non Applicable
Regeneron Pharmaceuticals, Bayer
Intraocular Inflammation, Suspected Endophthalmitis
12/22
09/23
NCT03297684: Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection

Active, not recruiting
N/A
40
US
Aflibercept Injection [Eylea]
Advanced Eye Research Associates
Diabetic Macular Edema
12/22
12/22
COCTAEyl, NCT03803631: CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea

Active, not recruiting
N/A
49
Europe
Centre Hospitalier Intercommunal Creteil, Bayer
AMD, Exudative Macular Degeneration
01/23
07/23
NCT03797547: Real Life Study in Myopic Neovascularization

Active, not recruiting
N/A
24
Europe
AFLIBERCEPT
Poitiers University Hospital
Myopic Choroidal Neovascularisation
01/23
01/23
ANDROMEDA, NCT03714308: Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.

Completed
N/A
554
Europe
Ivt. Aflibercept (Eylea, BAY86-5321)
Bayer
Macular Degeneration
03/23
05/23
CSCR, NCT05847049: Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy

Completed
N/A
16
RoW
Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy
Dar El Oyoun Hospital
Central Serous Chorioretinopathy
03/23
04/23
ChiCTR2300077486: High-dose aflibercept for treatment-resistant wet age-related macular degeneration: 1-year outcomes

Completed
N/A
20
 
Aflibercept 3mg intravitreal injection
Qingdao Eye Hospital of Shandong First Medical University; Qingdao Eye Hospital of Shandong First Medical University, Qingdao Eye Hospital introduced doctoral research funds
Wet age-related macular degeneration
 
 
RAZORBILL, NCT04662944: A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections

Completed
N/A
494
Europe, Canada
brolucizumab, ranibizumab, aflibercept
Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration
06/23
06/23
XTEND, NCT03939767: Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease

Completed
N/A
1563
Europe, Canada, RoW
Aflibercept (Eylea, BAY86-5321)
Bayer
Wet Age-related Macular Degeneration
07/23
10/23
OPHTH-010915, NCT02669953: Aflibercept in Recurrent or Persistent CNV

Recruiting
N/A
80
Europe
Aflibercept
Medical University of Vienna
Age Related Macular Degeneration, Intravitreal Injections, Diabetic Macular Edema
09/23
12/23
NCT06124677: Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments

Completed
N/A
46
Europe
Faricimab, Vabysmo (6 mg, 0.05 ml)
Rigshospitalet, Denmark
Neovascular Age-related Macular Degeneration
11/23
12/23
NCT02645266: Mean Visual Acuity Changes Following Five Injections of Aflibercept

Active, not recruiting
N/A
48
Canada
Aflibercept Injection [Eylea], Eylea treatment
McMaster University
Diabetic Macular Edema
09/24
12/24
NCT06231121: Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab

Completed
N/A
13
Europe
Faricimab, Vabysmo (6 mg, 0.05 ml)
Rigshospitalet, Denmark
Neovascular Age-related Macular Degeneration
01/24
01/24
ChiCTR2100049698: The association of single nucleotide polymorphism with response to anti-vascular endothelial growth factor treatment in Chinese polypoidal choroidal vasculopathy patients

Not yet recruiting
N/A
90
 
Intravenous injection of aflibercept
Chinese Academy of Medical Sciences Peking Union Medical College Hospital; Chinese Academy of Medical Sciences Peking Union Medical College Hospital, Special Fundation for Basic Research of Beijing, Tianjin, Hebei Cooperation
polypoidal choroidal vasculopathy
 
 
NCT06315556: An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)

Recruiting
N/A
200
Europe
Aflibercept (Eylea)
Bayer
Retinopathy of Prematurity, Preterm Infants
03/27
04/27
NCT05211804: Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse

Completed
N/A
31
Europe
Ophthalmic Drugs, Aflibercept, Bevacizumab, Ranibizumab
Sorlandet Hospital HF
Wet Macular Degeneration
05/24
05/24
 

Download Options